ID

34993

Descripción

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT02213744

Link

https://clinicaltrials.gov/show/NCT02213744

Palabras clave

Versiones (1)
  1. 7/2/19 7/2/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

7 de febrero de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT02213744

Inglés

Eligibility Breast Cancer NCT02213744

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients must have histologically or cytologically confirmed invasive cancer of the breast
Descripción

Invasive carcinoma of breast

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0853879
patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
Descripción

Advanced disease Locally | Neoplasm Metastasis | Excision Curative intent Unsuccessful

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0679246
UMLS CUI [1,2]
C1517927
UMLS CUI [2]
C0027627
UMLS CUI [3,1]
C0728940
UMLS CUI [3,2]
C1276305
UMLS CUI [3,3]
C1272705
patients must have her2-positive breast cancer as defined by asco/cap 2013 guidelines that is confirmed by a sponsor-designated central laboratory
Descripción

HER2-positive carcinoma of breast

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1960398
patients must have progressed on, or be intolerant to pertuzumab in the labc/mbc setting
Descripción

Disease Progression | Intolerance to Pertuzumab

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C1328025
patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the labc/mbc setting
Descripción

Disease Progression | Intolerance to Ado-trastuzumab emtansine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0242656
UMLS CUI [2,1]
C1744706
UMLS CUI [2,2]
C2935436
patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
Descripción

Trastuzumab Previous | Pertuzumab Previous

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C0205156
UMLS CUI [2,1]
C1328025
UMLS CUI [2,2]
C0205156
ecog performance status of 0 or 1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
Descripción

Doxorubicin | doxorubicin liposome | Epirubicin | Mitoxantrone | Anthracycline Derivative

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013089
UMLS CUI [2]
C0717726
UMLS CUI [3]
C0014582
UMLS CUI [4]
C0026259
UMLS CUI [5,1]
C0282564
UMLS CUI [5,2]
C1527240
subjects with central nervous system (cns) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment
Descripción

CNS metastases | Exception Treatment completed | Exception Stable status Without Symptoms | Exception Steroids Absent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0580352
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0205360
UMLS CUI [3,3]
C0332288
UMLS CUI [3,4]
C1457887
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0038317
UMLS CUI [4,3]
C0332197
patients with any class of new york heart association (nyha) chf or heart failure with preserved ejection fraction (hfpef)
Descripción

Congestive heart failure New York Heart Association Classification | Heart failure with preserved ejection fraction [HFpEF]

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0018802
UMLS CUI [1,2]
C1275491
UMLS CUI [2]
C4509226
patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
Descripción

Coronary Artery Disease | Myocardial Infarction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1956346
UMLS CUI [2]
C0027051
patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)
Descripción

Cardiac Arrhythmia Serious Treatment required for | Exception Controlled atrial fibrillation | Exception Paroxysmal supraventricular tachycardia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003811
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0332121
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0577699
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0030590
patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
Descripción

Trastuzumab Discontinued Due to Cardiotoxicity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0728747
UMLS CUI [1,2]
C1444662
UMLS CUI [1,3]
C0678226
UMLS CUI [1,4]
C0876994
patients with a history of lvef decline to below 50% during or after prior trastuzumab/lapatinib or other her2 directed therapy.
Descripción

Left ventricular ejection fraction | trastuzumab | lapatinib | HER2 Targeted Therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0428772
UMLS CUI [2]
C0728747
UMLS CUI [3]
C1506770
UMLS CUI [4,1]
C0069515
UMLS CUI [4,2]
C2985566
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT02213744

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Invasive carcinoma of breast
Item
patients must have histologically or cytologically confirmed invasive cancer of the breast
boolean
C0853879 (UMLS CUI [1])
Advanced disease Locally | Neoplasm Metastasis | Excision Curative intent Unsuccessful
Item
patients must have documented locally advanced/metastatic disease, defined by the investigator, which is not amenable to resection with curative intent.
boolean
C0679246 (UMLS CUI [1,1])
C1517927 (UMLS CUI [1,2])
C0027627 (UMLS CUI [2])
C0728940 (UMLS CUI [3,1])
C1276305 (UMLS CUI [3,2])
C1272705 (UMLS CUI [3,3])
HER2-positive carcinoma of breast
Item
patients must have her2-positive breast cancer as defined by asco/cap 2013 guidelines that is confirmed by a sponsor-designated central laboratory
boolean
C1960398 (UMLS CUI [1])
Disease Progression | Intolerance to Pertuzumab
Item
patients must have progressed on, or be intolerant to pertuzumab in the labc/mbc setting
boolean
C0242656 (UMLS CUI [1])
C1744706 (UMLS CUI [2,1])
C1328025 (UMLS CUI [2,2])
Disease Progression | Intolerance to Ado-trastuzumab emtansine
Item
patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the labc/mbc setting
boolean
C0242656 (UMLS CUI [1])
C1744706 (UMLS CUI [2,1])
C2935436 (UMLS CUI [2,2])
Trastuzumab Previous | Pertuzumab Previous
Item
patients must have been previously treated with trastuzumab in any setting (which may have been previously administered with or without pertuzumab)
boolean
C0728747 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C1328025 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
ECOG performance status
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Doxorubicin | doxorubicin liposome | Epirubicin | Mitoxantrone | Anthracycline Derivative
Item
patients who have previously been treated with doxorubicin, liposomal doxorubicin, epirubicin, mitoxantrone, or any other anthracycline derivative
boolean
C0013089 (UMLS CUI [1])
C0717726 (UMLS CUI [2])
C0014582 (UMLS CUI [3])
C0026259 (UMLS CUI [4])
C0282564 (UMLS CUI [5,1])
C1527240 (UMLS CUI [5,2])
CNS metastases | Exception Treatment completed | Exception Stable status Without Symptoms | Exception Steroids Absent
Item
subjects with central nervous system (cns) metastases, unless they have been treated and are stable without symptoms for 4 weeks after completion of treatment and must be off steroids for at least 4 weeks prior to enrollment
boolean
C0686377 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0580352 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
C0332288 (UMLS CUI [3,3])
C1457887 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C0038317 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Congestive heart failure New York Heart Association Classification | Heart failure with preserved ejection fraction [HFpEF]
Item
patients with any class of new york heart association (nyha) chf or heart failure with preserved ejection fraction (hfpef)
boolean
C0018802 (UMLS CUI [1,1])
C1275491 (UMLS CUI [1,2])
C4509226 (UMLS CUI [2])
Coronary Artery Disease | Myocardial Infarction
Item
patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months
boolean
C1956346 (UMLS CUI [1])
C0027051 (UMLS CUI [2])
Cardiac Arrhythmia Serious Treatment required for | Exception Controlled atrial fibrillation | Exception Paroxysmal supraventricular tachycardia
Item
patients with a known history of serious cardiac arrhythmias requiring treatment (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)
boolean
C0003811 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0332121 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0577699 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0030590 (UMLS CUI [3,2])
Trastuzumab Discontinued Due to Cardiotoxicity
Item
patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity
boolean
C0728747 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0678226 (UMLS CUI [1,3])
C0876994 (UMLS CUI [1,4])
Left ventricular ejection fraction | trastuzumab | lapatinib | HER2 Targeted Therapy
Item
patients with a history of lvef decline to below 50% during or after prior trastuzumab/lapatinib or other her2 directed therapy.
boolean
C0428772 (UMLS CUI [1])
C0728747 (UMLS CUI [2])
C1506770 (UMLS CUI [3])
C0069515 (UMLS CUI [4,1])
C2985566 (UMLS CUI [4,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial